Literature DB >> 7927999

Antibody-producing cells in peripheral blood and tonsils after oral treatment of children with bacterial ribosomes.

C Zanin1, P Perrin, M C Bene, A M Perruchet, G C Faure.   

Abstract

The efficacy of ribosomal preparations as mucosal immunostimulants was examined in the peripheral blood and tonsils of 14 children, before and after 28 days of oral treatment with D-53, a preparation of ribosomes from Klebsiella pneumoniae, Streptococcus pneumoniae, Haemophilus influenzae and Streptococcus pyogenes. Tonsils from 10 untreated children were used as controls. Immunofluorescence and ELISAspot were performed to analyse variations in the numbers of immunoglobulin-containing and immunoglobulin-secreting B-cells. Both isotypic and antigenic specificities of these two types of cells were investigated. Significant differences were observed after treatment in the peripheral blood as well as between tonsils from treated and untreated children. In the peripheral blood a significant increase in immunoglobulin-secreting cells directed against antigenic specificities of D-53 was the major change. In tonsils, higher numbers of specific immunoglobulin-containing and secreting cells, and higher numbers of IgA-secreting cells were induced in treated children. These data support the efficacy of D-53 as an oral immunostimulant.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7927999     DOI: 10.1016/0192-0561(94)90101-5

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  8 in total

Review 1.  Ribosomal immunotherapy for recurrent respiratory tract infections in children.

Authors:  Marie C Béné; Gilbert C Faure
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

2.  Ribosomal therapy in the treatment of recurrent acute adenoiditis.

Authors:  Renzo Mora; Massimo Dellepiane; Barbara Crippa; Luca Guastini; Valentina Santomauro; Angelo Salami
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-01-06       Impact factor: 2.503

Review 3.  Pharmacology of ribosomal immunotherapy.

Authors:  J Clot
Journal:  Drugs       Date:  1997       Impact factor: 9.546

4.  From Peyer's patches to tonsils. Specific stimulation with ribosomal immunotherapy.

Authors:  M C Béné; G C Faure
Journal:  Drugs       Date:  1997       Impact factor: 9.546

Review 5.  Prevention of recurrent respiratory tract infections in children using a ribosomal immunotherapeutic agent: a clinical review.

Authors:  Jean Bousquet; Alessandro Fiocchi
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

6.  Inhibition of Streptococcus pneumoniae adhesion by specific salivary IgA after oral immunisation with a ribosomal immunostimulant.

Authors:  L Hbabi-Haddioui; C Roques
Journal:  Drugs       Date:  1997       Impact factor: 9.546

7.  Cost effectiveness of immunoprophylaxis in the prevention of recurrent infectious rhinitis in adults.

Authors:  G Berdeaux; A Lafuma; A M Perruchet; F Fagnani
Journal:  Pharmacoeconomics       Date:  1998-09       Impact factor: 4.981

8.  Effectiveness of ribosomal fractions of Klebsiella pneumoniae, Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae and the membrane fraction of Kp (Ribomunyl) in the prevention of clinical recurrences of infectious rhinitis. Results of a multicenter double-blind placebo-controlled study.

Authors:  E Serrano; J P Demanez; A Morgon; C Chastang; P Van Cauwenberge
Journal:  Eur Arch Otorhinolaryngol       Date:  1997       Impact factor: 2.503

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.